ASCO 2026 preview – GSK gets an early GIST
Strategist-Frontline is set to begin, as the company reports first-line velzatinib data at ASCO.
New neoantigen approaches from Abogen and Odimma
ABO2109 and ODI-2001 are starting their first human studies.
Pfizer targets VEGF bispecific white space
The company diverges from Summit and Bristol/BioNTech with a pivotal endometrial trial.
SystImmune expands its iza-bren programme again
Relapsed biliary tract cancer, and ASCO, beckon.
AbbVie takes pivekimab pivotal
The phase 2/3 Revival trial will test a ven/aza combo in first-line AML.
Aktis takes a second asset into human trials
The recent Nasdaq entrant prepares to move AKY-2519 into the clinic.
Astellas starts a second pivotal degrader trial
The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
New prostate cancer hopes from Roche and Novartis
GDC-1261 and INR731 enter phase 1, but how do they act?
Merck makes a new move in Astra battle
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
